Vital Signs - The Analyst's Perspective - April 2015 Issue
The diagnostics and pharmaceutical giant Roche recently announced the acquisition of privately held CAPP diagnostics. This is one of many next-generation sequencing companies absorbed by Roche. The acquisition is aligned with its vision to expand on its next-generation sequencing diagnostics capabilities, especially in oncology.
CAPP has a ground-breaking, non-invasive liquid technology to detect circulating tumor DNA (ctDNA) with just a drop of blood. This acquisition not only places Roche in a strong position for non-invasive cancer detection, but also has the potential to provide valuable clinical trial support for its pharmaceutical and oncology drug pipelines.
The Analyst’s Perspective by Aish Vivekanandan, Industry Analyst, Life Sciences, North America
Roche has been steadily acquiring genomics companies like Signature Diagnostics, Bina Technologies and Genia Technologies to build technologies and offerings in the next-generation sequencing market, particularly on the clinical side. With Roche’s decreasing market shares over the years in the next-generation sequencing space, the company is hoping to get back in the game with these technology acquisitions.
These acquisitions come as no surprise as Roche suffered heavy blows when two of its clinical studies for breast cancer and Alzheimer’s disease failed, causing the largest stock backlash in a decade. The company has been scrambling to rectify the situation, turning to the promising next-generation sequencing market, not just in the research space, but also in drug discovery and having a deeper understanding of disease.
In addition to this, Roche has been trying to find the best differentiating system in the market, and CAPP has the best technology of the three recent acquisitions. For Roche, differentiation of its product is key in competing with market leaders Illumina and Life Technologies. CAPP Diagnostics’ technology is a catch in terms of product differentiation, but only time will tell if Roche can achieve a highly competitive product following these costly purchases.
About this report
This issue of Vital Signs, released on May 12, 2015, discusses Roche's acquisition of CAPP Diagnostics, IBM's announcments of deals with Apple, Johnson & Johnson, and Medtronic, 2014 US prescription drug spending trends, and DuPont's acquisition of Taxon Biosciences.
Electronic Access - Site License Fulfilled By Publisher
Electronic Access - Global site License Fulfilled By Publisher